Get the Stockscreener App
10.32
38.03%
2.845
After Hours:
10.34
0.015
+0.15%
Sensei Biotherapeutics Inc stock is traded at $10.32, with a volume of 210.07K.
It is up +38.03% in the last 24 hours and up +16.67% over the past month.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
See More
Previous Close:
$7.48
Open:
$7.48
24h Volume:
210.07K
Relative Volume:
16.66
Market Cap:
$13.02M
Revenue:
-
Net Income/Loss:
$-29.80M
P/E Ratio:
-8.6765
EPS:
-1.19
Net Cash Flow:
$-25.19M
1W Performance:
+47.92%
1M Performance:
+16.67%
6M Performance:
+9.84%
1Y Performance:
-21.21%
1-Day Range:
$7.365
$10.99
1-Week Range:
$6.325
$10.99
52-Week Range:
$5.00
$17.40
Sensei Biotherapeutics Inc Stock (SNSE) Company Profile
Name
Sensei Biotherapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
10.32 | 9.43M | 0 | -29.80M | -25.19M | -1.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Sensei Biotherapeutics Inc Stock (SNSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Jun-29-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Mar-01-21 | Initiated | Citigroup | Buy |
| Mar-01-21 | Initiated | Oppenheimer | Outperform |
| Mar-01-21 | Initiated | Piper Sandler | Overweight |
View All
Sensei Biotherapeutics Inc Stock (SNSE) Latest News
When is Sensei Biotherapeutics Inc. stock expected to show significant growthRetirement Planning Watchlist For Fast Growth - jammulinksnews.com
How volatile is Sensei Biotherapeutics Inc. stock compared to the marketFinancial News Outlook For 2025 - jammulinksnews.com
How Sensei Biotherapeutics Inc. stock performs during market volatilityFree Real-Time Analysis With Entry Targets - Newser
Sensei Biotherapeutics Inc.’s volatility index tracking explainedFree Community Shared Smart Money Signals - Newser
What institutions are buying Sensei Biotherapeutics Inc. stock nowHigh Probability Trade Plan with Indicators - Newser
How to manage a losing position in Sensei Biotherapeutics Inc.Weekly Movement Forecast With Chart Signals - Newser
Is Sensei Biotherapeutics Inc. stock overhyped or has real potentialStrategy Chart for Real-Time Trade Flow - Newser
Is Sensei Biotherapeutics Inc. a growth stock or a value stockExpert Picks Target Finder For Consistent Profits - jammulinksnews.com
Is it the right time to buy Sensei Biotherapeutics Inc. stockDaily Trading Guidance With Proven Results - jammulinksnews.com
Smart tools for monitoring Sensei Biotherapeutics Inc.’s price actionFree High Conviction Intraday Stock Signals - Newser
Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug At the European Society for Medical Oncology Congress 2025 - MarketScreener
Sensei Biotherapeutics to Present Clinical Data from the - GlobeNewswire
Sensei Biotherapeutics to present cancer therapy data at ESMO 2025 By Investing.com - Investing.com India
Sensei Biotherapeutics to present cancer therapy data at ESMO 2025 - Investing.com
Sensei Biotherapeutics to Present Clinical Data from the Phase 1 - GuruFocus
Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025 - The Manila Times
Breakthrough Cancer Drug Trial Results: Sensei's PD-1 Combo Therapy Shows Promise for Advanced Tumors - Stock Titan
Using data tools to time your Sensei Biotherapeutics Inc. exitTechnical Setup Guide for Daily Watchlist - Newser
What MACD signals say about Sensei Biotherapeutics Inc.Smart Risk Entry Zone Technical Analysis - Newser
Why Sensei Biotherapeutics Inc. stock attracts strong analyst attentionFree Profit Target Stock Opportunity Monitor - Newser
Chart based analysis of Sensei Biotherapeutics Inc. trendsReal Time Alert System for Market Moves - Newser
Sensei Biotherapeutics Inc. Reversal Rally May Surprise BearsProven Entry Plan With Low Risk Shared - metal.it
Is Sensei Biotherapeutics Inc. Stock a Good Fit for Conservative InvestorsChart-Based Trade Entries Gain Analyst Support - beatles.ru
What makes Sensei Biotherapeutics Inc. stock price move sharplyDaily Trading Strategy To Watch Now - jammulinksnews.com
What is the risk reward ratio of investing in Sensei Biotherapeutics Inc. stockRapid growth trajectories - jammulinksnews.com
Applying Wyckoff theory to Sensei Biotherapeutics Inc. stockRSI and MACD Signal Summary with Trends - Newser
How does Sensei Biotherapeutics Inc. generate profit in a changing economyPhenomenal wealth increase - jammulinksnews.com
Sensei Biotherapeutics Inc. stock momentum explained Free Real Trader Watchlist of Hot Stocks - Newser
Chart based analysis of Sensei Biotherapeutics Inc. trends Chart Confirmation Setup with ROI Signals - Newser
What is Sensei Biotherapeutics Inc. company’s growth strategyUnlock superior stock analysis tools - jammulinksnews.com
Sensei Biotherapeutics Inc. Company Revenue and Profit Trends: A Deep DiveFree Stock Market Insider Analysis - metal.it
Published on: 2025-07-27 18:31:22 - jammulinksnews.com
Is Sensei Biotherapeutics Inc. a good long term investmentSuperior stock selection - PrintWeekIndia
What analysts say about Sensei Biotherapeutics Inc. stockSpectacular growth rates - Autocar Professional
Sensei Biotherapeutics Inc. Stock Analysis and ForecastPhenomenal returns - Autocar Professional
What drives Sensei Biotherapeutics Inc. stock priceFree Predictions - Autocar Professional
Sensei Biotherapeutics Inc Stock (SNSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):